Mice Model Market

The global mice model market in terms of revenue was estimated to be worth $1.5 billion in 2024 and is poised to reach $2.2 billion by 2029, growing at a CAGR of 8.1% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The expansion of the market is primarily propelled by their genetical identity with humans, resulting in greater reproducibility of experimental results. The rising pipeline of novel drug therapies is also supporting the growth of this market.

Mice Model Market- Global Forecast to 2029

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the Mice Model Market

Global Mice model market Dynamics

DRIVER: Rising demand for personalized medicines in oncology

The increasing incidence and prevalence of chronic diseases like cancer is a pivotal driving factor behind the burgeoning growth of the market. As diseases such as cancer, become more prevalent, personalized medicine approaches facilitated by mice model research are gaining prominence. For instance, the rising number of cancer cases has led to a demand for tailored treatments based on individual genetic profiles, driving the adoption of drug development strategies. According to World Health Organization estimates, worldwide, an estimated 20 million new cancer cases and 10 million cancer-related deaths occurred in 2020. Projections suggest a frightening 60% surge in the cancer burden within the next two decades, imposing greater strain on healthcare systems, individuals, and communities. This market growth is further fueled by the need for more effective and personalized therapeutic interventions in the face of a growing global health burden.

RESTRAINT: Ethical concerns and regulatory interventions

Ethical concerns and regulatory constraints pose significant impediments to the market, necessitating careful consideration by researchers and organizations such as biosafety considerations, GLP compliance standards, and animal welfare compliance. The ethical considerations surrounding animal use in scientific research, particularly with mice models, have intensified, placing greater emphasis on humane treatment. Entities engaged in biomedical research are obligated to strictly adhere to ethical guidelines, prioritizing the humane care and welfare of animals involved in experiments. Despite concerted efforts to prioritize the well-being of mice in research, persistent concerns revolve around potential pain, distress, and suffering. Ethical dilemmas arise from issues such as insufficient housing, painful procedures, and a lack of enrichment activities, prompting critical reflections on the ethical treatment of these animals. These challenges, rooted in ethical considerations, not only impede the growth of the market but also prompt crucial reflections on striking a balance between scientific advancements and the ethical treatment of animals.

OPPORTUNITY: Rising demand for disease specific mice models

The rising demand for disease-specific mouse models presents a substantial growth opportunity within the market. Researchers and pharmaceutical companies increasingly recognize the importance of tailored models that faithfully replicate specific human diseases, enabling more accurate preclinical studies and therapeutic development. For instance, the rising prevalence of cancer-related research has led to a surge in demand for mouse models engineered to mimic distinct types of cancer, facilitating detailed investigations into disease mechanisms and the evaluation of potential treatments. Moreover, the demand for neurodegenerative disease models, such as Alzheimer's and Parkinson's, is on the rise, reflecting a growing emphasis on understanding and addressing complex neurological disorders. For instance, Mice models with induced Alzheimer's or Parkinson's disease are crucial for understanding these complex neurological conditions and testing potential therapies.

CHALLENGE: Genetic & Phenotypic variability

The challenge of genotype and phenotypic variability poses a complex obstacle in the market. Genetic diversity within mouse strains, even those considered to be inbred, can result in variations in both genotype and phenotype. This variability can influence research outcomes, hindering the reproducibility and reliability of experimental results. For instance, in studies related to drug development or disease modeling, subtle genetic differences among individual mice can lead to diverse responses to treatments, making it challenging to draw consistent conclusions. Additionally, factors such as environmental conditions, housing, and diet can further contribute to phenotypic variations among mice within the same strain. This inherent variability complicates the establishment of standardized protocols and can increase the difficulty of comparing results across different studies or research facilities.

Global Mice Model Industry Ecosystem Analysis

The mice model market ecosystem comprises raw material suppliers, product/model & service providers, regulatory authorities, and end users, such as academic & research institutes, contract research organizations, and pharmaceutical & biotechnology companies

CRISPR/Cas9 segment held a dominant share in the technology segment in the mice model industry

Based on the technology, the mice model market has been segmented into CRISPR/CAS9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies. In 2023, CRISPR/Cas9 accounted for the largest share of the market. This is attributed to its capacity to offer in-depth insights into individual genetic variations, enabling personalized medicine by optimizing drug selection based on unique genetic profiles.

The drug discovery & development segment of mice model industry is expected to register fastest growth during the forecast period.

Based on the application, the mice model market has been segmented into drug discovery & development, research application, and personalized medicine. In 2023, drug discovery & development accounted for the largest market share and is expected to achieve the highest CAGR during the projected period. The key drivers of drug discovery & development in the market include their ability of mice model to mimic human physiology and disease pathology. Mice models share genetic, physiological, and behavioral similarities with humans, making them valuable tools for studying disease mechanisms, evaluating drug efficacy, and assessing safety profiles

North America accounted for the largest share in mice model industry in 2023

Geographically, the mice model market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and the Africa. North America held the dominant share followed by Europe. North America has been a leader in supporting research for the development of innovative in new therapy. Thus, the development of novel therapies and R&D efforts taken by countries such as US and Canada, and rising number of preclinical research projects in the region are contributing to the growth of the North America market.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the global mice model market include Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), GemPharmatech (China), Cyagen (US), Shanghai Model Organisms Center, Inc. (China), JSR Corporation (Japan), Biocytogen (China), TRANS GENIC INC. (Japan), Ozgene Pty Ltd. (Australia), Taconic Biosciences, Inc. (US), TransCure bioServices (France), Harbour BioMed (China), Marshall BioResources (US), genOway (France), Vivo Bio Tech Ltd. (India), ingenious targeting laboratory (US), Janvier Labs (France), Applied StemCell (US), Creative Animodel (US), JOINN Laboratories Co., Ltd. (China), Creative Biolabs (US), Crescendo Biologics (UK), Aragen Life Sciences (India), and PolyGene (Switzerland).

Scope of the Mice Model Industry

This report categorizes the mice model market to forecast revenue and analyze trends in each of the following submarkets:

By Model Type & Service

• Model Type
  • Inbred Mice
  • Genetically Engineered Mice
  • Hybrid/Congenic Mice
  • Outbred Mice
• Service
  • Breeding
  • Cryopreservation
  • Rederivation
  • Quarantine
  • Other services

By Technology

• CRISPR/CAS9
• Microinjection
• Embryonic Stem cell Injection
• Nuclear Transfer
• Other Technologies

By Therapeutic Area

• Oncology
• Metabolic Diseases
• Immunology
• Neurology
• Cardiovascular Diseases
• Other Therapeutic Diseases

By Application

• Drug Discovery & Development
• Research Application
• Personalized Medicine

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• CROs & CDMOs

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East & Africa
  • Middle East
    • GCC Countries
      • Saudi Arabia
      • United Ara Emirates
      • Rest of GCC Countries
    • Rest of Middle East (RoME)
  • Africa

Recent Developments of Mice Model Industry:

• In December 2023, Biocytogen entered into a licensing agreement with Nuerocrine Biosciences. This agreement grants Neurocrine Biosciences the right to license selected antibodies for therapeutic product development, manufacturing, and commercialization for all uses worldwide.
• In July 2022, GemPharmatech has entered into a strategic licensing agreement with Charles River Laboratories to distribute its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America.
• In April 2022, Inotiv acquired Histion, LLC. The acquisition is a strategic development that reflects the company’s capabilities in expanding capabilities for surgical models and pathology services.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst